Rothschild Redb Upgrades Novo Nordisk A/S (NYSE:NVO) to Strong-Buy

Key Points

• Novo Nordisk A/S has received an upgrade to a Strong Buy rating from Rothschild Redb, changing its previous "hold" rating.
• Despite the upgrade, other analysts show mixed opinions with one lowering the price target to $70 while another downgraded the stock to a "strong sell."
• The company's recent earnings report showed a profit of $0.97 per share, exceeding expectations, with a net margin of 35.60%.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was upgraded by investment analysts at Rothschild Redb from a "hold" rating to a "strong-buy" rating in a research report issued on Tuesday,Zacks.com reports.

NVO has been the subject of several other reports. UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Barclays reissued an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Zacks Research downgraded Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 20th. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective for the company in a research note on Wednesday, August 13th. Finally, Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $81.00.

Novo Nordisk A/S Price Performance

NVO stock traded down $0.40 during midday trading on Tuesday, reaching $61.45. The stock had a trading volume of 12,824,513 shares, compared to its average volume of 13,342,038. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $129.48. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The company's fifty day simple moving average is $56.88 and its 200 day simple moving average is $65.26. The company has a market cap of $274.37 billion, a price-to-earnings ratio of 16.88, a price-to-earnings-growth ratio of 2.33 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Institutional investors have recently modified their holdings of the company. Copeland Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. purchased a new stake in Novo Nordisk A/S in the 1st quarter worth about $27,000. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Stone House Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $30,000. Finally, NewSquare Capital LLC raised its stake in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company's stock worth $31,000 after purchasing an additional 282 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.